LON:REDX Redx Pharma (REDX) Share Price, News & Analysis GBX 15 +3.60 (+31.58%) (As of 04/30/2024) Add Share Share Stock Analysis Stock AnalysisHeadlines About Redx Pharma Stock (LON:REDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Redx Pharma alerts:Sign Up Key Stats Today's Range 11.42▼ 3350-Day Range 15▼ 1552-Week Range 4▼ 37.90Volume1.42 million shsAverage Volume707,637 shsMarket Capitalization£58.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRedx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.Read More… JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Receive REDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address REDX Stock News HeadlinesRedx Pharma (LON:REDX) Share Price Crosses Below Fifty Day Moving Average - Here's WhyNovember 21 at 4:33 AM | americanbankingnews.comBig Pharma lacks motive to prep for new pandemicsSeptember 11, 2024 | reuters.comBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.November 21, 2024 | Genesis Gold Group (Ad)BUSINESS LIVE: BT fined over 999 failings; Entain names CEO; UK dividends hit record highJuly 23, 2024 | msn.comRedx Pharma Plc Shares now trading on JP JenkinsMay 1, 2024 | markets.businessinsider.comRedx boss scooped up shares after revealing London Stock Exchange exitApril 20, 2024 | msn.comRedx Pharma PLC REDXApril 13, 2024 | morningstar.comExodus from Aim leaves chorus of questions in its wakeApril 13, 2024 | thetimes.co.ukSee More Headlines REDX Stock Analysis - Frequently Asked Questions How have REDX shares performed this year? Redx Pharma's stock was trading at GBX 22 on January 1st, 2024. Since then, REDX shares have decreased by 31.8% and is now trading at GBX 15. View the best growth stocks for 2024 here. How were Redx Pharma's earnings last quarter? Redx Pharma Plc (LON:REDX) announced its quarterly earnings data on Monday, November, 19th. The company reported ($7.00) earnings per share for the quarter, missing analysts' consensus estimates of ($6.50) by $0.50. How do I buy shares of Redx Pharma? Shares of REDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Redx Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Redx Pharma investors own include AutoZone (AZO), Barclays (BARC), Salesforce (CRM), Digital Globe Services (DGS), Intel (INTC), Legal & General Group (LGEN) and OptiBiotix Health (OPTI). Company Calendar Last Earnings11/19/2018Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:REDX CUSIPN/A CIKN/A Webredxpharma.com Phone+44-151-7064747FaxN/AEmployees101Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-33,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-180.80% Return on Assets-43.95% Debt Debt-to-Equity Ratio527.00 Current Ratio1.11 Quick Ratio1.93 Sales & Book Value Annual Sales£4.20 million Price / Sales13.89 Cash FlowGBX 2.87 per share Price / Cash Flow5.23 Book ValueGBX 1 per share Price / Book15.00Miscellaneous Outstanding Shares388,990,000Free FloatN/AMarket Cap£58.35 million OptionableNot Optionable Beta-0.53 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (LON:REDX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redx Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Redx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.